http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 01 Jun 2026 08:10:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++425++++++++Rallybio+Corp++++++++++++++++++++++++++Filed+by%3A+Rallybio+Corp/26579685.html si-local-file:///var/storage/secattach/20260601/26579685.html http://www.streetinsider.com/SEC+Filings/Form++425++++++++Rallybio+Corp++++++++++++++++++++++++++Filed+by%3A+Rallybio+Corp/26579685.html Mon, 01 Jun 2026 08:10:00 -0400 O.51068808 RLYB http://www.streetinsider.com/SEC+Filings/Form++425++++++++Rallybio+Corp++++++++++++++++++++++++++Filed+by%3A+Rallybio+Corp/26579685.html si-local-file:///var/storage/secattach/20260601/26579685.html http://www.streetinsider.com/SEC+Filings/Form++425++++++++Rallybio+Corp++++++++++++++++++++++++++Filed+by%3A+Rallybio+Corp/26579685.html Mon, 01 Jun 2026 08:10:00 -0400 O.51068808 RLYB http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Rallybio+Corp+++++++++++++For%3A+May+31/26579669.html si-local-file:///var/storage/secattach/20260601/26579669.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Rallybio+Corp+++++++++++++For%3A+May+31/26579669.html Mon, 01 Jun 2026 08:08:00 -0400 O.51068808 RLYB http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Rallybio+Corp+++++++++++++For%3A+May+31/26579669.html si-local-file:///var/storage/secattach/20260601/26579669.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Rallybio+Corp+++++++++++++For%3A+May+31/26579669.html Mon, 01 Jun 2026 08:08:00 -0400 O.51068808 RLYB http://www.streetinsider.com/Equity+Offerings/Rallybio+and+Avenzo+agree+to+merge+with+%24215+million+private+placement/26579619.html <p>Rallybio Corporation (NASDAQ: RLYB) and Avenzo Therapeutics announced a definitive merger agreement under which Rallybio will acquire the clinical-stage oncology company. The combined entity will operate as Avenzo Therapeutics and trade on NASDAQ under the ticker "AVZO."</p> <p>Concurrent with the merger, Avenzo secured $215 million in gross proceeds through an oversubscribed private placement. Investors include Blackstone Multi-Asset Investing, T. Rowe Price Investment Management, Vivo Capital, OrbiMed, and other institutional investors. The financing is expected to fund operations into late 2028.</p> <p>Upon closing, pre-transaction Rallybio shareholders will own approximately 2.8% of the combined company, while pre-transaction Avenzo shareholders and new investors will hold http://www.streetinsider.com/Equity+Offerings/Rallybio+and+Avenzo+agree+to+merge+with+%24215+million+private+placement/26579619.html Mon, 01 Jun 2026 08:02:17 -0400 A.00157782 A.05453562 A.07414818 A.10371245 A.14185667 A.26662531 A.36817542 A.50203581 A.50216726 A.50216776 O.00046809 O.00057334 O.03227691 O.21612337 O.22066148 O.22801920 O.25213119 O.49896957 O.51068808 O.51342686 O.54144732 RLYB http://www.streetinsider.com/Equity+Offerings/Rallybio+and+Avenzo+agree+to+merge+with+%24215+million+private+placement/26579619.html <p>Rallybio Corporation (NASDAQ: RLYB) and Avenzo Therapeutics announced a definitive merger agreement under which Rallybio will acquire the clinical-stage oncology company. The combined entity will operate as Avenzo Therapeutics and trade on NASDAQ under the ticker "AVZO."</p> <p>Concurrent with the merger, Avenzo secured $215 million in gross proceeds through an oversubscribed private placement. Investors include Blackstone Multi-Asset Investing, T. Rowe Price Investment Management, Vivo Capital, OrbiMed, and other institutional investors. The financing is expected to fund operations into late 2028.</p> <p>Upon closing, pre-transaction Rallybio shareholders will own approximately 2.8% of the combined company, while pre-transaction Avenzo shareholders and new investors will hold http://www.streetinsider.com/Equity+Offerings/Rallybio+and+Avenzo+agree+to+merge+with+%24215+million+private+placement/26579619.html Mon, 01 Jun 2026 08:02:17 -0400 A.00157782 A.05453562 A.07414818 A.10371245 A.14185667 A.26662531 A.36817542 A.50203581 A.50216726 A.50216776 O.00046809 O.00057334 O.03227691 O.21612337 O.22066148 O.22801920 O.25213119 O.49896957 O.51068808 O.51342686 O.54144732 RLYB http://www.streetinsider.com/Equity+Offerings/Rallybio+and+Avenzo+agree+to+merge+with+%24215+million+private+placement/26579619.html <p>Rallybio Corporation (NASDAQ: RLYB) and Avenzo Therapeutics announced a definitive merger agreement under which Rallybio will acquire the clinical-stage oncology company. The combined entity will operate as Avenzo Therapeutics and trade on NASDAQ under the ticker "AVZO."</p> <p>Concurrent with the merger, Avenzo secured $215 million in gross proceeds through an oversubscribed private placement. Investors include Blackstone Multi-Asset Investing, T. Rowe Price Investment Management, Vivo Capital, OrbiMed, and other institutional investors. The financing is expected to fund operations into late 2028.</p> <p>Upon closing, pre-transaction Rallybio shareholders will own approximately 2.8% of the combined company, while pre-transaction Avenzo shareholders and new investors will hold http://www.streetinsider.com/Equity+Offerings/Rallybio+and+Avenzo+agree+to+merge+with+%24215+million+private+placement/26579619.html Mon, 01 Jun 2026 08:02:17 -0400 A.00157782 A.05453562 A.07414818 A.10371245 A.14185667 A.26662531 A.36817542 A.50203581 A.50216726 A.50216776 O.00046809 O.00057334 O.03227691 O.21612337 O.22066148 O.22801920 O.25213119 O.49896957 O.51068808 O.51342686 O.54144732 RLYB http://www.streetinsider.com/Equity+Offerings/Rallybio+and+Avenzo+agree+to+merge+with+%24215+million+private+placement/26579619.html <p>Rallybio Corporation (NASDAQ: RLYB) and Avenzo Therapeutics announced a definitive merger agreement under which Rallybio will acquire the clinical-stage oncology company. The combined entity will operate as Avenzo Therapeutics and trade on NASDAQ under the ticker "AVZO."</p> <p>Concurrent with the merger, Avenzo secured $215 million in gross proceeds through an oversubscribed private placement. Investors include Blackstone Multi-Asset Investing, T. Rowe Price Investment Management, Vivo Capital, OrbiMed, and other institutional investors. The financing is expected to fund operations into late 2028.</p> <p>Upon closing, pre-transaction Rallybio shareholders will own approximately 2.8% of the combined company, while pre-transaction Avenzo shareholders and new investors will hold http://www.streetinsider.com/Equity+Offerings/Rallybio+and+Avenzo+agree+to+merge+with+%24215+million+private+placement/26579619.html Mon, 01 Jun 2026 08:02:17 -0400 A.00157782 A.05453562 A.07414818 A.10371245 A.14185667 A.26662531 A.36817542 A.50203581 A.50216726 A.50216776 O.00046809 O.00057334 O.03227691 O.21612337 O.22066148 O.22801920 O.25213119 O.49896957 O.51068808 O.51342686 O.54144732 RLYB http://www.streetinsider.com/Equity+Offerings/Rallybio+and+Avenzo+agree+to+merge+with+%24215+million+private+placement/26579619.html <p>Rallybio Corporation (NASDAQ: RLYB) and Avenzo Therapeutics announced a definitive merger agreement under which Rallybio will acquire the clinical-stage oncology company. The combined entity will operate as Avenzo Therapeutics and trade on NASDAQ under the ticker "AVZO."</p> <p>Concurrent with the merger, Avenzo secured $215 million in gross proceeds through an oversubscribed private placement. Investors include Blackstone Multi-Asset Investing, T. Rowe Price Investment Management, Vivo Capital, OrbiMed, and other institutional investors. The financing is expected to fund operations into late 2028.</p> <p>Upon closing, pre-transaction Rallybio shareholders will own approximately 2.8% of the combined company, while pre-transaction Avenzo shareholders and new investors will hold http://www.streetinsider.com/Equity+Offerings/Rallybio+and+Avenzo+agree+to+merge+with+%24215+million+private+placement/26579619.html Mon, 01 Jun 2026 08:02:17 -0400 A.00157782 A.05453562 A.07414818 A.10371245 A.14185667 A.26662531 A.36817542 A.50203581 A.50216726 A.50216776 O.00046809 O.00057334 O.03227691 O.21612337 O.22066148 O.22801920 O.25213119 O.49896957 O.51068808 O.51342686 O.54144732 RLYB http://www.streetinsider.com/Equity+Offerings/Rallybio+and+Avenzo+agree+to+merge+with+%24215+million+private+placement/26579619.html <p>Rallybio Corporation (NASDAQ: RLYB) and Avenzo Therapeutics announced a definitive merger agreement under which Rallybio will acquire the clinical-stage oncology company. The combined entity will operate as Avenzo Therapeutics and trade on NASDAQ under the ticker "AVZO."</p> <p>Concurrent with the merger, Avenzo secured $215 million in gross proceeds through an oversubscribed private placement. Investors include Blackstone Multi-Asset Investing, T. Rowe Price Investment Management, Vivo Capital, OrbiMed, and other institutional investors. The financing is expected to fund operations into late 2028.</p> <p>Upon closing, pre-transaction Rallybio shareholders will own approximately 2.8% of the combined company, while pre-transaction Avenzo shareholders and new investors will hold http://www.streetinsider.com/Equity+Offerings/Rallybio+and+Avenzo+agree+to+merge+with+%24215+million+private+placement/26579619.html Mon, 01 Jun 2026 08:02:17 -0400 A.00157782 A.05453562 A.07414818 A.10371245 A.14185667 A.26662531 A.36817542 A.50203581 A.50216726 A.50216776 O.00046809 O.00057334 O.03227691 O.21612337 O.22066148 O.22801920 O.25213119 O.49896957 O.51068808 O.51342686 O.54144732 RLYB http://www.streetinsider.com/Equity+Offerings/Rallybio+and+Avenzo+agree+to+merge+with+%24215+million+private+placement/26579619.html <p>Rallybio Corporation (NASDAQ: RLYB) and Avenzo Therapeutics announced a definitive merger agreement under which Rallybio will acquire the clinical-stage oncology company. The combined entity will operate as Avenzo Therapeutics and trade on NASDAQ under the ticker "AVZO."</p> <p>Concurrent with the merger, Avenzo secured $215 million in gross proceeds through an oversubscribed private placement. Investors include Blackstone Multi-Asset Investing, T. Rowe Price Investment Management, Vivo Capital, OrbiMed, and other institutional investors. The financing is expected to fund operations into late 2028.</p> <p>Upon closing, pre-transaction Rallybio shareholders will own approximately 2.8% of the combined company, while pre-transaction Avenzo shareholders and new investors will hold http://www.streetinsider.com/Equity+Offerings/Rallybio+and+Avenzo+agree+to+merge+with+%24215+million+private+placement/26579619.html Mon, 01 Jun 2026 08:02:17 -0400 A.00157782 A.05453562 A.07414818 A.10371245 A.14185667 A.26662531 A.36817542 A.50203581 A.50216726 A.50216776 O.00046809 O.00057334 O.03227691 O.21612337 O.22066148 O.22801920 O.25213119 O.49896957 O.51068808 O.51342686 O.54144732 RLYB http://www.streetinsider.com/Equity+Offerings/Rallybio+and+Avenzo+agree+to+merge+with+%24215+million+private+placement/26579619.html <p>Rallybio Corporation (NASDAQ: RLYB) and Avenzo Therapeutics announced a definitive merger agreement under which Rallybio will acquire the clinical-stage oncology company. The combined entity will operate as Avenzo Therapeutics and trade on NASDAQ under the ticker "AVZO."</p> <p>Concurrent with the merger, Avenzo secured $215 million in gross proceeds through an oversubscribed private placement. Investors include Blackstone Multi-Asset Investing, T. Rowe Price Investment Management, Vivo Capital, OrbiMed, and other institutional investors. The financing is expected to fund operations into late 2028.</p> <p>Upon closing, pre-transaction Rallybio shareholders will own approximately 2.8% of the combined company, while pre-transaction Avenzo shareholders and new investors will hold http://www.streetinsider.com/Equity+Offerings/Rallybio+and+Avenzo+agree+to+merge+with+%24215+million+private+placement/26579619.html Mon, 01 Jun 2026 08:02:17 -0400 A.00157782 A.05453562 A.07414818 A.10371245 A.14185667 A.26662531 A.36817542 A.50203581 A.50216726 A.50216776 O.00046809 O.00057334 O.03227691 O.21612337 O.22066148 O.22801920 O.25213119 O.49896957 O.51068808 O.51342686 O.54144732 RLYB http://www.streetinsider.com/Equity+Offerings/Rallybio+and+Avenzo+agree+to+merge+with+%24215+million+private+placement/26579619.html <p>Rallybio Corporation (NASDAQ: RLYB) and Avenzo Therapeutics announced a definitive merger agreement under which Rallybio will acquire the clinical-stage oncology company. The combined entity will operate as Avenzo Therapeutics and trade on NASDAQ under the ticker "AVZO."</p> <p>Concurrent with the merger, Avenzo secured $215 million in gross proceeds through an oversubscribed private placement. Investors include Blackstone Multi-Asset Investing, T. Rowe Price Investment Management, Vivo Capital, OrbiMed, and other institutional investors. The financing is expected to fund operations into late 2028.</p> <p>Upon closing, pre-transaction Rallybio shareholders will own approximately 2.8% of the combined company, while pre-transaction Avenzo shareholders and new investors will hold http://www.streetinsider.com/Equity+Offerings/Rallybio+and+Avenzo+agree+to+merge+with+%24215+million+private+placement/26579619.html Mon, 01 Jun 2026 08:02:17 -0400 A.00157782 A.05453562 A.07414818 A.10371245 A.14185667 A.26662531 A.36817542 A.50203581 A.50216726 A.50216776 O.00046809 O.00057334 O.03227691 O.21612337 O.22066148 O.22801920 O.25213119 O.49896957 O.51068808 O.51342686 O.54144732 RLYB http://www.streetinsider.com/Equity+Offerings/Rallybio+and+Avenzo+agree+to+merge+with+%24215+million+private+placement/26579619.html <p>Rallybio Corporation (NASDAQ: RLYB) and Avenzo Therapeutics announced a definitive merger agreement under which Rallybio will acquire the clinical-stage oncology company. The combined entity will operate as Avenzo Therapeutics and trade on NASDAQ under the ticker "AVZO."</p> <p>Concurrent with the merger, Avenzo secured $215 million in gross proceeds through an oversubscribed private placement. Investors include Blackstone Multi-Asset Investing, T. Rowe Price Investment Management, Vivo Capital, OrbiMed, and other institutional investors. The financing is expected to fund operations into late 2028.</p> <p>Upon closing, pre-transaction Rallybio shareholders will own approximately 2.8% of the combined company, while pre-transaction Avenzo shareholders and new investors will hold http://www.streetinsider.com/Equity+Offerings/Rallybio+and+Avenzo+agree+to+merge+with+%24215+million+private+placement/26579619.html Mon, 01 Jun 2026 08:02:17 -0400 A.00157782 A.05453562 A.07414818 A.10371245 A.14185667 A.26662531 A.36817542 A.50203581 A.50216726 A.50216776 O.00046809 O.00057334 O.03227691 O.21612337 O.22066148 O.22801920 O.25213119 O.49896957 O.51068808 O.51342686 O.54144732 RLYB http://www.streetinsider.com/Equity+Offerings/Rallybio+and+Avenzo+agree+to+merge+with+%24215+million+private+placement/26579619.html <p>Rallybio Corporation (NASDAQ: RLYB) and Avenzo Therapeutics announced a definitive merger agreement under which Rallybio will acquire the clinical-stage oncology company. The combined entity will operate as Avenzo Therapeutics and trade on NASDAQ under the ticker "AVZO."</p> <p>Concurrent with the merger, Avenzo secured $215 million in gross proceeds through an oversubscribed private placement. Investors include Blackstone Multi-Asset Investing, T. Rowe Price Investment Management, Vivo Capital, OrbiMed, and other institutional investors. The financing is expected to fund operations into late 2028.</p> <p>Upon closing, pre-transaction Rallybio shareholders will own approximately 2.8% of the combined company, while pre-transaction Avenzo shareholders and new investors will hold http://www.streetinsider.com/Equity+Offerings/Rallybio+and+Avenzo+agree+to+merge+with+%24215+million+private+placement/26579619.html Mon, 01 Jun 2026 08:02:17 -0400 A.00157782 A.05453562 A.07414818 A.10371245 A.14185667 A.26662531 A.36817542 A.50203581 A.50216726 A.50216776 O.00046809 O.00057334 O.03227691 O.21612337 O.22066148 O.22801920 O.25213119 O.49896957 O.51068808 O.51342686 O.54144732 RLYB http://www.streetinsider.com/Equity+Offerings/Rallybio+and+Avenzo+agree+to+merge+with+%24215+million+private+placement/26579619.html <p>Rallybio Corporation (NASDAQ: RLYB) and Avenzo Therapeutics announced a definitive merger agreement under which Rallybio will acquire the clinical-stage oncology company. The combined entity will operate as Avenzo Therapeutics and trade on NASDAQ under the ticker "AVZO."</p> <p>Concurrent with the merger, Avenzo secured $215 million in gross proceeds through an oversubscribed private placement. Investors include Blackstone Multi-Asset Investing, T. Rowe Price Investment Management, Vivo Capital, OrbiMed, and other institutional investors. The financing is expected to fund operations into late 2028.</p> <p>Upon closing, pre-transaction Rallybio shareholders will own approximately 2.8% of the combined company, while pre-transaction Avenzo shareholders and new investors will hold http://www.streetinsider.com/Equity+Offerings/Rallybio+and+Avenzo+agree+to+merge+with+%24215+million+private+placement/26579619.html Mon, 01 Jun 2026 08:02:17 -0400 A.00157782 A.05453562 A.07414818 A.10371245 A.14185667 A.26662531 A.36817542 A.50203581 A.50216726 A.50216776 O.00046809 O.00057334 O.03227691 O.21612337 O.22066148 O.22801920 O.25213119 O.49896957 O.51068808 O.51342686 O.54144732 RLYB http://www.streetinsider.com/Equity+Offerings/Rallybio+and+Avenzo+agree+to+merge+with+%24215+million+private+placement/26579619.html <p>Rallybio Corporation (NASDAQ: RLYB) and Avenzo Therapeutics announced a definitive merger agreement under which Rallybio will acquire the clinical-stage oncology company. The combined entity will operate as Avenzo Therapeutics and trade on NASDAQ under the ticker "AVZO."</p> <p>Concurrent with the merger, Avenzo secured $215 million in gross proceeds through an oversubscribed private placement. Investors include Blackstone Multi-Asset Investing, T. Rowe Price Investment Management, Vivo Capital, OrbiMed, and other institutional investors. The financing is expected to fund operations into late 2028.</p> <p>Upon closing, pre-transaction Rallybio shareholders will own approximately 2.8% of the combined company, while pre-transaction Avenzo shareholders and new investors will hold http://www.streetinsider.com/Equity+Offerings/Rallybio+and+Avenzo+agree+to+merge+with+%24215+million+private+placement/26579619.html Mon, 01 Jun 2026 08:02:17 -0400 A.00157782 A.05453562 A.07414818 A.10371245 A.14185667 A.26662531 A.36817542 A.50203581 A.50216726 A.50216776 O.00046809 O.00057334 O.03227691 O.21612337 O.22066148 O.22801920 O.25213119 O.49896957 O.51068808 O.51342686 O.54144732 RLYB http://www.streetinsider.com/Equity+Offerings/Rallybio+and+Avenzo+agree+to+merge+with+%24215+million+private+placement/26579619.html <p>Rallybio Corporation (NASDAQ: RLYB) and Avenzo Therapeutics announced a definitive merger agreement under which Rallybio will acquire the clinical-stage oncology company. The combined entity will operate as Avenzo Therapeutics and trade on NASDAQ under the ticker "AVZO."</p> <p>Concurrent with the merger, Avenzo secured $215 million in gross proceeds through an oversubscribed private placement. Investors include Blackstone Multi-Asset Investing, T. Rowe Price Investment Management, Vivo Capital, OrbiMed, and other institutional investors. The financing is expected to fund operations into late 2028.</p> <p>Upon closing, pre-transaction Rallybio shareholders will own approximately 2.8% of the combined company, while pre-transaction Avenzo shareholders and new investors will hold http://www.streetinsider.com/Equity+Offerings/Rallybio+and+Avenzo+agree+to+merge+with+%24215+million+private+placement/26579619.html Mon, 01 Jun 2026 08:02:17 -0400 A.00157782 A.05453562 A.07414818 A.10371245 A.14185667 A.26662531 A.36817542 A.50203581 A.50216726 A.50216776 O.00046809 O.00057334 O.03227691 O.21612337 O.22066148 O.22801920 O.25213119 O.49896957 O.51068808 O.51342686 O.54144732 RLYB http://www.streetinsider.com/Equity+Offerings/Rallybio+and+Avenzo+agree+to+merge+with+%24215+million+private+placement/26579619.html <p>Rallybio Corporation (NASDAQ: RLYB) and Avenzo Therapeutics announced a definitive merger agreement under which Rallybio will acquire the clinical-stage oncology company. The combined entity will operate as Avenzo Therapeutics and trade on NASDAQ under the ticker "AVZO."</p> <p>Concurrent with the merger, Avenzo secured $215 million in gross proceeds through an oversubscribed private placement. Investors include Blackstone Multi-Asset Investing, T. Rowe Price Investment Management, Vivo Capital, OrbiMed, and other institutional investors. The financing is expected to fund operations into late 2028.</p> <p>Upon closing, pre-transaction Rallybio shareholders will own approximately 2.8% of the combined company, while pre-transaction Avenzo shareholders and new investors will hold http://www.streetinsider.com/Equity+Offerings/Rallybio+and+Avenzo+agree+to+merge+with+%24215+million+private+placement/26579619.html Mon, 01 Jun 2026 08:02:17 -0400 A.00157782 A.05453562 A.07414818 A.10371245 A.14185667 A.26662531 A.36817542 A.50203581 A.50216726 A.50216776 O.00046809 O.00057334 O.03227691 O.21612337 O.22066148 O.22801920 O.25213119 O.49896957 O.51068808 O.51342686 O.54144732 RLYB http://www.streetinsider.com/Equity+Offerings/Rallybio+and+Avenzo+agree+to+merge+with+%24215+million+private+placement/26579619.html <p>Rallybio Corporation (NASDAQ: RLYB) and Avenzo Therapeutics announced a definitive merger agreement under which Rallybio will acquire the clinical-stage oncology company. The combined entity will operate as Avenzo Therapeutics and trade on NASDAQ under the ticker "AVZO."</p> <p>Concurrent with the merger, Avenzo secured $215 million in gross proceeds through an oversubscribed private placement. Investors include Blackstone Multi-Asset Investing, T. Rowe Price Investment Management, Vivo Capital, OrbiMed, and other institutional investors. The financing is expected to fund operations into late 2028.</p> <p>Upon closing, pre-transaction Rallybio shareholders will own approximately 2.8% of the combined company, while pre-transaction Avenzo shareholders and new investors will hold http://www.streetinsider.com/Equity+Offerings/Rallybio+and+Avenzo+agree+to+merge+with+%24215+million+private+placement/26579619.html Mon, 01 Jun 2026 08:02:17 -0400 A.00157782 A.05453562 A.07414818 A.10371245 A.14185667 A.26662531 A.36817542 A.50203581 A.50216726 A.50216776 O.00046809 O.00057334 O.03227691 O.21612337 O.22066148 O.22801920 O.25213119 O.49896957 O.51068808 O.51342686 O.54144732 RLYB http://www.streetinsider.com/Equity+Offerings/Rallybio+and+Avenzo+agree+to+merge+with+%24215+million+private+placement/26579619.html <p>Rallybio Corporation (NASDAQ: RLYB) and Avenzo Therapeutics announced a definitive merger agreement under which Rallybio will acquire the clinical-stage oncology company. The combined entity will operate as Avenzo Therapeutics and trade on NASDAQ under the ticker "AVZO."</p> <p>Concurrent with the merger, Avenzo secured $215 million in gross proceeds through an oversubscribed private placement. Investors include Blackstone Multi-Asset Investing, T. Rowe Price Investment Management, Vivo Capital, OrbiMed, and other institutional investors. The financing is expected to fund operations into late 2028.</p> <p>Upon closing, pre-transaction Rallybio shareholders will own approximately 2.8% of the combined company, while pre-transaction Avenzo shareholders and new investors will hold http://www.streetinsider.com/Equity+Offerings/Rallybio+and+Avenzo+agree+to+merge+with+%24215+million+private+placement/26579619.html Mon, 01 Jun 2026 08:02:17 -0400 A.00157782 A.05453562 A.07414818 A.10371245 A.14185667 A.26662531 A.36817542 A.50203581 A.50216726 A.50216776 O.00046809 O.00057334 O.03227691 O.21612337 O.22066148 O.22801920 O.25213119 O.49896957 O.51068808 O.51342686 O.54144732 RLYB http://www.streetinsider.com/Equity+Offerings/Rallybio+and+Avenzo+agree+to+merge+with+%24215+million+private+placement/26579619.html <p>Rallybio Corporation (NASDAQ: RLYB) and Avenzo Therapeutics announced a definitive merger agreement under which Rallybio will acquire the clinical-stage oncology company. The combined entity will operate as Avenzo Therapeutics and trade on NASDAQ under the ticker "AVZO."</p> <p>Concurrent with the merger, Avenzo secured $215 million in gross proceeds through an oversubscribed private placement. Investors include Blackstone Multi-Asset Investing, T. Rowe Price Investment Management, Vivo Capital, OrbiMed, and other institutional investors. The financing is expected to fund operations into late 2028.</p> <p>Upon closing, pre-transaction Rallybio shareholders will own approximately 2.8% of the combined company, while pre-transaction Avenzo shareholders and new investors will hold http://www.streetinsider.com/Equity+Offerings/Rallybio+and+Avenzo+agree+to+merge+with+%24215+million+private+placement/26579619.html Mon, 01 Jun 2026 08:02:17 -0400 A.00157782 A.05453562 A.07414818 A.10371245 A.14185667 A.26662531 A.36817542 A.50203581 A.50216726 A.50216776 O.00046809 O.00057334 O.03227691 O.21612337 O.22066148 O.22801920 O.25213119 O.49896957 O.51068808 O.51342686 O.54144732 RLYB http://www.streetinsider.com/Equity+Offerings/Rallybio+and+Avenzo+agree+to+merge+with+%24215+million+private+placement/26579619.html <p>Rallybio Corporation (NASDAQ: RLYB) and Avenzo Therapeutics announced a definitive merger agreement under which Rallybio will acquire the clinical-stage oncology company. The combined entity will operate as Avenzo Therapeutics and trade on NASDAQ under the ticker "AVZO."</p> <p>Concurrent with the merger, Avenzo secured $215 million in gross proceeds through an oversubscribed private placement. Investors include Blackstone Multi-Asset Investing, T. Rowe Price Investment Management, Vivo Capital, OrbiMed, and other institutional investors. The financing is expected to fund operations into late 2028.</p> <p>Upon closing, pre-transaction Rallybio shareholders will own approximately 2.8% of the combined company, while pre-transaction Avenzo shareholders and new investors will hold http://www.streetinsider.com/Equity+Offerings/Rallybio+and+Avenzo+agree+to+merge+with+%24215+million+private+placement/26579619.html Mon, 01 Jun 2026 08:02:17 -0400 A.00157782 A.05453562 A.07414818 A.10371245 A.14185667 A.26662531 A.36817542 A.50203581 A.50216726 A.50216776 O.00046809 O.00057334 O.03227691 O.21612337 O.22066148 O.22801920 O.25213119 O.49896957 O.51068808 O.51342686 O.54144732 RLYB http://www.streetinsider.com/Equity+Offerings/Rallybio+and+Avenzo+agree+to+merge+with+%24215+million+private+placement/26579619.html <p>Rallybio Corporation (NASDAQ: RLYB) and Avenzo Therapeutics announced a definitive merger agreement under which Rallybio will acquire the clinical-stage oncology company. The combined entity will operate as Avenzo Therapeutics and trade on NASDAQ under the ticker "AVZO."</p> <p>Concurrent with the merger, Avenzo secured $215 million in gross proceeds through an oversubscribed private placement. Investors include Blackstone Multi-Asset Investing, T. Rowe Price Investment Management, Vivo Capital, OrbiMed, and other institutional investors. The financing is expected to fund operations into late 2028.</p> <p>Upon closing, pre-transaction Rallybio shareholders will own approximately 2.8% of the combined company, while pre-transaction Avenzo shareholders and new investors will hold http://www.streetinsider.com/Equity+Offerings/Rallybio+and+Avenzo+agree+to+merge+with+%24215+million+private+placement/26579619.html Mon, 01 Jun 2026 08:02:17 -0400 A.00157782 A.05453562 A.07414818 A.10371245 A.14185667 A.26662531 A.36817542 A.50203581 A.50216726 A.50216776 O.00046809 O.00057334 O.03227691 O.21612337 O.22066148 O.22801920 O.25213119 O.49896957 O.51068808 O.51342686 O.54144732 RLYB http://www.streetinsider.com/Equity+Offerings/Rallybio+and+Avenzo+agree+to+merge+with+%24215+million+private+placement/26579619.html <p>Rallybio Corporation (NASDAQ: RLYB) and Avenzo Therapeutics announced a definitive merger agreement under which Rallybio will acquire the clinical-stage oncology company. The combined entity will operate as Avenzo Therapeutics and trade on NASDAQ under the ticker "AVZO."</p> <p>Concurrent with the merger, Avenzo secured $215 million in gross proceeds through an oversubscribed private placement. Investors include Blackstone Multi-Asset Investing, T. Rowe Price Investment Management, Vivo Capital, OrbiMed, and other institutional investors. The financing is expected to fund operations into late 2028.</p> <p>Upon closing, pre-transaction Rallybio shareholders will own approximately 2.8% of the combined company, while pre-transaction Avenzo shareholders and new investors will hold http://www.streetinsider.com/Equity+Offerings/Rallybio+and+Avenzo+agree+to+merge+with+%24215+million+private+placement/26579619.html Mon, 01 Jun 2026 08:02:17 -0400 A.00157782 A.05453562 A.07414818 A.10371245 A.14185667 A.26662531 A.36817542 A.50203581 A.50216726 A.50216776 O.00046809 O.00057334 O.03227691 O.21612337 O.22066148 O.22801920 O.25213119 O.49896957 O.51068808 O.51342686 O.54144732 RLYB